KraneShares MSCI All China Health Care Index ETF (KURE) seeks to track the MSCI China All Shares Health Care 10/40 Index, which measures the performance of Chinese healthcare companies including pharmaceuticals, biotechnology, medical devices, and healthcare services across mainland China, Hong Kong, and U.S.-listed Chinese ADRs.
How It Works
KURE uses a passively managed, market-capitalization-weighted approach that mirrors its benchmark index composition. The fund holds Chinese healthcare stocks in proportion to their market value, with quarterly rebalancing to maintain index alignment. Holdings include A-shares from Shanghai and Shenzhen exchanges, H-shares from Hong Kong, and American Depositary Receipts of Chinese companies. The ETF provides concentrated exposure to China's rapidly growing healthcare sector through approximately 50-80 holdings.
Key Features
- Pure-play access to China's healthcare boom, capturing growth from aging demographics and rising healthcare spending
- Includes A-shares typically difficult for foreign investors to access directly through traditional brokerage accounts
- Concentrated sector bet with higher growth potential than broad China market ETFs during healthcare expansion
Risks
- This ETF can lose significant value from Chinese regulatory crackdowns on healthcare companies, as seen with pharmaceutical pricing controls
- Currency risk from yuan fluctuations can amplify losses, as most holdings trade in Chinese yuan or Hong Kong dollars
- Geopolitical tensions between U.S. and China could trigger delisting risks for ADR holdings or broader market selloffs
Who Should Own This
Best suited as a satellite holding (5-15% of portfolio) for aggressive growth investors with 3+ year time horizons seeking China healthcare exposure. High risk tolerance required due to emerging market volatility, regulatory uncertainty, and sector concentration. Appropriate for investors bullish on China's demographic trends and healthcare modernization.